Immunicum's Patent Application Regarding the Company’s Core-Technology for Therapeutic Cancer Vaccination Using Allogeneic Dendritic Cells is Being Approved in the U.S.

Published: Oct 25, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Gothenburg, Sweden, 2013-10-25 08:53 CEST (GLOBE NEWSWIRE) -- The United States Patent and Trademark Office (USPTO), has issued a notice of allowance regarding patent application 11/603,819 and thus intends to approve Immunicum’s patent application to protect the Company’s core-technology in the U.S. market.

Help employers find you! Check out all the jobs and post your resume.

Back to news